Cargando…

Cellular uptake and in vitro antitumor efficacy of composite liposomes for neutron capture therapy

BACKGROUND: Neutron capture therapy for glioblastoma has focused mainly on the use of (10)B as neutron capture isotope. However, (157)Gd offers several advantages over boron, such as higher cross section for thermal neutrons and the possibility to perform magnetic resonance imaging during neutron ir...

Descripción completa

Detalles Bibliográficos
Autores principales: Peters, Tanja, Grunewald, Catrin, Blaickner, Matthias, Ziegner, Markus, Schütz, Christian, Iffland, Dorothee, Hampel, Gabriele, Nawroth, Thomas, Langguth, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349485/
https://www.ncbi.nlm.nih.gov/pubmed/25889824
http://dx.doi.org/10.1186/s13014-015-0342-7
_version_ 1782360035539550208
author Peters, Tanja
Grunewald, Catrin
Blaickner, Matthias
Ziegner, Markus
Schütz, Christian
Iffland, Dorothee
Hampel, Gabriele
Nawroth, Thomas
Langguth, Peter
author_facet Peters, Tanja
Grunewald, Catrin
Blaickner, Matthias
Ziegner, Markus
Schütz, Christian
Iffland, Dorothee
Hampel, Gabriele
Nawroth, Thomas
Langguth, Peter
author_sort Peters, Tanja
collection PubMed
description BACKGROUND: Neutron capture therapy for glioblastoma has focused mainly on the use of (10)B as neutron capture isotope. However, (157)Gd offers several advantages over boron, such as higher cross section for thermal neutrons and the possibility to perform magnetic resonance imaging during neutron irradiation, thereby combining therapy and diagnostics. We have developed different liposomal formulations of gadolinium-DTPA (Magnevist®) for application in neutron capture therapy of glioblastoma. The formulations were characterized physicochemically and tested in vitro in a glioma cell model for their effectiveness. METHODS: Liposomes entrapping gadolinium-DTPA as neutron capture agent were manufactured via lipid/film-extrusion method and characterized with regard to size, entrapment efficiency and in vitro release. For neutron irradiation, F98 and LN229 glioma cells were incubated with the newly developed liposomes and subsequently irradiated at the thermal column of the TRIGA reactor in Mainz. The dose rate derived from neutron irradiation with (157)Gd as neutron capturing agent was calculated via Monte Carlo simulations and set in relation to the respective cell survival. RESULTS: The liposomal Gd-DTPA reduced cell survival of F98 and LN229 cells significantly. Differences in liposomal composition of the formulations led to distinctly different outcome in cell survival. The amount of cellular Gd was not at all times proportional to cell survival, indicating that intracellular deposition of formulated Gd has a major influence on cell survival. The majority of the dose contribution arises from photon cross irradiation compared to a very small Gd-related dose. CONCLUSIONS: Liposomal gadolinium formulations represent a promising approach for neutron capture therapy of glioblastoma cells. The liposome composition determines the uptake and the survival of cells following radiation, presumably due to different uptake pathways of liposomes and intracellular deposition of gadolinium-DTPA. Due to the small range of the Auger and conversion electrons produced in (157)Gd capture, the proximity of Gd-atoms to cellular DNA is a crucial factor for infliction of lethal damage. Furthermore, Gd-containing liposomes may be used as MRI contrast agents for diagnostic purposes and surveillance of tumor targeting, thus enabling a theranostic approach for tumor therapy.
format Online
Article
Text
id pubmed-4349485
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43494852015-03-05 Cellular uptake and in vitro antitumor efficacy of composite liposomes for neutron capture therapy Peters, Tanja Grunewald, Catrin Blaickner, Matthias Ziegner, Markus Schütz, Christian Iffland, Dorothee Hampel, Gabriele Nawroth, Thomas Langguth, Peter Radiat Oncol Research BACKGROUND: Neutron capture therapy for glioblastoma has focused mainly on the use of (10)B as neutron capture isotope. However, (157)Gd offers several advantages over boron, such as higher cross section for thermal neutrons and the possibility to perform magnetic resonance imaging during neutron irradiation, thereby combining therapy and diagnostics. We have developed different liposomal formulations of gadolinium-DTPA (Magnevist®) for application in neutron capture therapy of glioblastoma. The formulations were characterized physicochemically and tested in vitro in a glioma cell model for their effectiveness. METHODS: Liposomes entrapping gadolinium-DTPA as neutron capture agent were manufactured via lipid/film-extrusion method and characterized with regard to size, entrapment efficiency and in vitro release. For neutron irradiation, F98 and LN229 glioma cells were incubated with the newly developed liposomes and subsequently irradiated at the thermal column of the TRIGA reactor in Mainz. The dose rate derived from neutron irradiation with (157)Gd as neutron capturing agent was calculated via Monte Carlo simulations and set in relation to the respective cell survival. RESULTS: The liposomal Gd-DTPA reduced cell survival of F98 and LN229 cells significantly. Differences in liposomal composition of the formulations led to distinctly different outcome in cell survival. The amount of cellular Gd was not at all times proportional to cell survival, indicating that intracellular deposition of formulated Gd has a major influence on cell survival. The majority of the dose contribution arises from photon cross irradiation compared to a very small Gd-related dose. CONCLUSIONS: Liposomal gadolinium formulations represent a promising approach for neutron capture therapy of glioblastoma cells. The liposome composition determines the uptake and the survival of cells following radiation, presumably due to different uptake pathways of liposomes and intracellular deposition of gadolinium-DTPA. Due to the small range of the Auger and conversion electrons produced in (157)Gd capture, the proximity of Gd-atoms to cellular DNA is a crucial factor for infliction of lethal damage. Furthermore, Gd-containing liposomes may be used as MRI contrast agents for diagnostic purposes and surveillance of tumor targeting, thus enabling a theranostic approach for tumor therapy. BioMed Central 2015-02-22 /pmc/articles/PMC4349485/ /pubmed/25889824 http://dx.doi.org/10.1186/s13014-015-0342-7 Text en © Peters et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Peters, Tanja
Grunewald, Catrin
Blaickner, Matthias
Ziegner, Markus
Schütz, Christian
Iffland, Dorothee
Hampel, Gabriele
Nawroth, Thomas
Langguth, Peter
Cellular uptake and in vitro antitumor efficacy of composite liposomes for neutron capture therapy
title Cellular uptake and in vitro antitumor efficacy of composite liposomes for neutron capture therapy
title_full Cellular uptake and in vitro antitumor efficacy of composite liposomes for neutron capture therapy
title_fullStr Cellular uptake and in vitro antitumor efficacy of composite liposomes for neutron capture therapy
title_full_unstemmed Cellular uptake and in vitro antitumor efficacy of composite liposomes for neutron capture therapy
title_short Cellular uptake and in vitro antitumor efficacy of composite liposomes for neutron capture therapy
title_sort cellular uptake and in vitro antitumor efficacy of composite liposomes for neutron capture therapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349485/
https://www.ncbi.nlm.nih.gov/pubmed/25889824
http://dx.doi.org/10.1186/s13014-015-0342-7
work_keys_str_mv AT peterstanja cellularuptakeandinvitroantitumorefficacyofcompositeliposomesforneutroncapturetherapy
AT grunewaldcatrin cellularuptakeandinvitroantitumorefficacyofcompositeliposomesforneutroncapturetherapy
AT blaicknermatthias cellularuptakeandinvitroantitumorefficacyofcompositeliposomesforneutroncapturetherapy
AT ziegnermarkus cellularuptakeandinvitroantitumorefficacyofcompositeliposomesforneutroncapturetherapy
AT schutzchristian cellularuptakeandinvitroantitumorefficacyofcompositeliposomesforneutroncapturetherapy
AT ifflanddorothee cellularuptakeandinvitroantitumorefficacyofcompositeliposomesforneutroncapturetherapy
AT hampelgabriele cellularuptakeandinvitroantitumorefficacyofcompositeliposomesforneutroncapturetherapy
AT nawroththomas cellularuptakeandinvitroantitumorefficacyofcompositeliposomesforneutroncapturetherapy
AT langguthpeter cellularuptakeandinvitroantitumorefficacyofcompositeliposomesforneutroncapturetherapy